The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

B Ramsey, L; G Johnson, S; E Caudle, K; E Haidar, C; Voora, D; A Wilke, R; D Maxwell, W; L McLeod, H; M Krauss, R; M Roden, D; Feng, Q; M Cooper-DeHoff, R; Gong, L; E Klein, T; Wadelius, M; Niemi, M

doi:10.1038/clpt.2014.125

Public

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Shared by NobleBlocks on Oct 1, 2014 • 12:00 AM UTC

Authors:

L B Ramsey

S G Johnson

K E Caudle

Abstract

Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting th...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!